The influence of CYP2C19 polymorphism on the eradication of Helicobacter pylori:: A randomized study of lansoprazole and rabeprazole

被引：0
作者：
Jung, H. Y. [1 ]
Song, H. J. [1 ]
Choi, K. D. [1 ]
Chung, J. W. [1 ]
Kim, D. H. [1 ]
Kim, J. H. [1 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
来源：
HELICOBACTER | 2007年 / 12卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：429 / 429
页数：1
相关论文
共 50 条
  • [31] Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers
    Saitoh, T
    Fukushima, Y
    Otsuka, H
    Hirakawa, J
    Mori, H
    Asano, T
    Ishikawa, T
    Katsube, T
    Ogawa, K
    Ohkawa, S
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (10) : 1811 - 1817
  • [32] Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations
    Itagaki, F
    Homma, M
    Yuzawa, K
    Nishimura, M
    Naito, S
    Ueda, N
    Ohkohchi, N
    Kohda, Y
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 (08) : 1055 - 1059
  • [33] CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole
    Adachi, K
    Katsube, T
    Kawamura, A
    Takashima, T
    Yuki, M
    Amano, K
    Ishihara, S
    Fukuda, R
    Watanabe, M
    Kinoshita, Y
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) : 1259 - 1266
  • [34] CYP2C19 genotypes in Germany and influence on treatment of Helicobacter pylori infection
    Kirsch, C
    Schneider-Brachert, W
    Grossmann, D
    Stolte, M
    Lehn, N
    Miehlke, S
    GASTROENTEROLOGY, 2003, 124 (04) : A180 - A180
  • [35] The efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism:: Author's reply
    Sheu, BS
    Kao, AW
    Cheng, HC
    Hunag, SF
    Chen, TW
    Lu, CC
    Wu, JJ
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 22 (03) : 275 - 276
  • [36] Impact of genotypic differences in CYP2C19 status on the eradication of Helicobacter pylori in Caucasian patients
    Schwab, M
    Schaeffeler, E
    Klotz, U
    Treiber, G
    GASTROENTEROLOGY, 2003, 124 (04) : A361 - A361
  • [37] Effect of cyp2c19 polymorphism on the eradication rate of Helicobacter pylori infection by pantoprazole or esomeprazole based triple therapy in Korea
    Kang, Jung mook
    Kim, Nayoung
    Kim, Joo sung
    Jung, Hyun chae
    Song, In sung
    GASTROENTEROLOGY, 2007, 132 (04) : A613 - A613
  • [38] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    Katsuki, H
    Nakamura, C
    Arimori, K
    Fujiyama, S
    Nakano, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) : 391 - 396
  • [39] Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects
    H. Katsuki
    C. Nakamura
    K. Arimori
    S. Fujiyama
    M. Nakano
    European Journal of Clinical Pharmacology, 1997, 52 : 391 - 396
  • [40] A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism
    Miyoshi, M
    Mizuno, M
    Ishiki, K
    Nagahara, Y
    Maga, T
    Torigoe, T
    Nasu, J
    Okada, H
    Yokota, K
    Oguma, K
    Tsuji, T
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (07) : 723 - 728
12345